RecruitingNot ApplicableNCT06720597

EndoPAT Device for Endothelial Dysfunction in ED

Utilizing EndoPAT Device for Endothelial Dysfunction Assessment in Erectile Dysfunction and Hormonal Therapy

Sponsor

University of California, Irvine

Enrollment

120 participants

Start Date

Aug 13, 2025

Study Type

INTERVENTIONAL

Conditions

Hypogonadism, Male Erectile Dysfunction Endothelial Dysfunction

Summary

To assess endothelial dysfunction in young men (aged 30-50) with vasculogenic ED identified through penile Doppler ultrasound. To evaluate changes in endothelial function using EndoPAT before and 3-6 months after daily low-dose phosphodiesterase type 5 (PDE5) inhibitor therapy. To investigate endothelial function alterations in hypogonadal patients before and 3-6 months after initiating testosterone (T) therapy

Eligibility

Sex: MALEMin Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Daily low-dose PDE5 inhibitor therapy and a drug called Testosterone therapy as per clinical guidelines. for people with endothelial dysfunction, erectile dysfunction, and other related conditions. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGDaily low-dose PDE5 inhibitor therapy

Neither arm of the study includes a control group, and the two interventions will not be compared directly. The primary objective is to evaluate endothelial function using the EndoPAT device at baseline, 3 months, and 6 months following the intervention in each arm.

DRUGTestosterone therapy as per clinical guidelines.